Literature DB >> 27822622

[Diagnostics and treatment of cholangiocellular carcinoma].

L Zender1, N P Malek2.   

Abstract

Cholangiocellular carcinoma (CCA) is the second most frequent primary liver carcinoma and is an aggressive tumor, which is mostly diagnosed in advanced stages. The overall survival is poor. Histpathological analysis of tumor biopsies or cytological analysis of biliary brushings can be used to confirm the diagnosis. A differentiation is made between distal, perihilar and intrahepatic CCA. The anatomical position determines the diagnostic and therapeutic strategy. Before diagnostic or therapeutic measures are undertaken it is essential to resolve biliary obstruction via endoscopic stenting or percutaneous biliary drainage. Depending on the tumor stage curative treatment options comprise radical surgical resection with hepaticojejunostomy or in selected cases liver transplantation. For intrahepatic or distal CCA liver transplantation is not indicated. In the palliative setting systemic chemotherapy with gemcitabine and cisplatin leads to a significant improvement in survival time.

Entities:  

Keywords:  Biopsy, bile ducts; Cholestasis; Gemcitabine/cisplatin; Liver transplantation; Surgery, cholangiocellular carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27822622     DOI: 10.1007/s00108-016-0128-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  94 in total

Review 1.  Liver transplantation for cholangiocarcinoma.

Authors:  Charles B Rosen; Julie K Heimbach; Gregory J Gores
Journal:  Transpl Int       Date:  2010-05-20       Impact factor: 3.782

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States.

Authors:  Luciana McLean; Tushar Patel
Journal:  Liver Int       Date:  2006-11       Impact factor: 5.828

Review 4.  Intrahepatic cholangiocarcinoma: the role of imaging in detection and staging.

Authors:  B S Kuszyk; P Soyer; D A Bluemke; E K Fishman
Journal:  Crit Rev Diagn Imaging       Date:  1997

5.  Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment.

Authors:  Ya-yong Li; Hao Li; Pin Lv; Gang Liu; Xiao-rong Li; Bu-ning Tian; Dao-jin Chen
Journal:  J Gastrointest Surg       Date:  2011-01-19       Impact factor: 3.452

6.  Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.

Authors:  Alain Gelibter; Paola Malaguti; Serena Di Cosimo; Emilio Bria; Enzo Maria Ruggeri; Paolo Carlini; Fabio Carboni; Giuseppe Maria Ettorre; Mario Pellicciotta; Diana Giannarelli; Edmondo Terzoli; Francesco Cognetti; Michele Milella
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

8.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

9.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.

Authors:  Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

10.  Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.

Authors:  Joung-Soon Jang; Ho Yeong Lim; In Gyu Hwang; Hong Suk Song; NaeChoon Yoo; SoYoung Yoon; Yeul Hong Kim; Eunsik Park; Jae Ho Byun; Myung Ah Lee; Suk Joong Oh; Kyung Hee Lee; Bong Seog Kim; Sang Cheul Oh; Sam Yong Kim; Sang Jae Lee
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-04       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.